CN Patent

CN118593504B — 氘可来昔替尼或其盐在制备pvns药物方面的新用途

Assigned to Peking University Third Hospital Peking University Third Clinical Medical College · Expires 2025-03-18 · 1y expired

What this patent protects

本发明涉及氘可来昔替尼或其盐在制备PVNS药物方面的新用途，具体提供了氘可来昔替尼或其药学上可接受的盐在制备治疗和/或缓解色素沉着绒毛结节性滑膜炎的药物方面的应用，所述氘可来昔替尼或其药学上可接受的盐作为活性成分。本发明通过研究发现，应用氘可来昔替尼处理与PVNS滑膜病变密切相关的细胞，多项实验结果的指标优于现有药物培西达替尼。相关实验表明氘可来昔替尼具有治疗和/或缓解PVNS的作用，具有良好的临床应用前景。

USPTO Abstract

本发明涉及氘可来昔替尼或其盐在制备PVNS药物方面的新用途，具体提供了氘可来昔替尼或其药学上可接受的盐在制备治疗和/或缓解色素沉着绒毛结节性滑膜炎的药物方面的应用，所述氘可来昔替尼或其药学上可接受的盐作为活性成分。本发明通过研究发现，应用氘可来昔替尼处理与PVNS滑膜病变密切相关的细胞，多项实验结果的指标优于现有药物培西达替尼。相关实验表明氘可来昔替尼具有治疗和/或缓解PVNS的作用，具有良好的临床应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN118593504B
Jurisdiction
CN
Classification
—
Expires
2025-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Peking University Third Hospital Peking University Third Clinical Medical College
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.